TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23322527
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Risperidone tablet; Dr. Reddy's Laboratories Ltd.)
Study: 23322527
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Risperdal(®) tablet; Xian‐Janssen Pharmaceutical Ltd.)
Study: 21262278
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration in a laboratory experiment
Study: 17879021
Drug: Nicorandil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (4 mg bolus injection followed by 8 mg/h infusion for 24 h)
Study: 11565068
Drug: piperacillin‐tazobactam plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin‐tazobactam plus amikacin (7.5 mg/kg twice daily intravenously)
Study: 8152772
Drug: Topical 0.01%
Normalized name: tretinoin topical 0.01% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.01% mitomycin C for 5 days
Study: 8152772
Drug: Topical 0.02%
Normalized name: tretinoin topical 0.02% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.02% mitomycin C for 5 days
Study: 3134560
Drug: 2-liter prepackaged
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-liter prepackaged enteral diet delivery system (2000 kcal, 12 g N)
Study: 30221457
Drug: 75% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75% of usual insulin degludec (IDeg) dose
Study: 30221457
Drug: 100% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% of usual insulin degludec (IDeg) dose
Study: 23963821
Drug: Surgical oophorectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical oophorectomy plus tamoxifen therapy
Study: 19080698
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor and levofloxacin based triple therapy
Study: 12496537
Drug: GLY-GLN (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLY-GLN (0.5 g/kg/24 h)
Study: 12496537
Drug: ALA-GLN (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-GLN (0.5 g/kg/24 h)
Study: 12496537
Drug: Vamin (GLN-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vamin (GLN-free amino acid solution; control group)
Study: 12145055
Drug: Mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.2 mg/kg injected over 10 s
Study: 12145055
Drug: Mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.2 mg/kg injected over 30 s
Study: 10204554
Drug: 24 hours
Normalized name: PATCH, TRANSDERMAL 24 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hours of intravenous cefoxitin (1 g q6h)
Study: 10204554
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of intravenous cefoxitin
Study: 2079453
Drug: Teicoplanin (non-toxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (non-toxic antibiotic)
Study: 7418154
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg/day for 8 weeks
Study: 29256406
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (250 mg/day of magnesium oxide)
Study: 21454236
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro with meals and basal insulin glargine
Study: 19358497
Drug: Meridian three-combined
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meridian three-combined therapy (thread embedding, blood-letting puncture, auricular point pressing)
Study: 19358497
Drug: Di yin
Normalized name: di-isopropylammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di yin Tablets (5 tablets, twice daily)
Study: 19358497
Drug: Meridian three-combined
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meridian three-combined therapy
Study: 19358497
Drug: Di yin
Normalized name: di-isopropylammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di yin Tablets
Study: 10983644
Drug: Cidofovir 5
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cidofovir 5 mg/kg once weekly for 2 weeks followed by low-dose maintenance cidofovir therapy (3 mg/kg)
Study: 10983644
Drug: Cidofovir 5
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cidofovir 5 mg/kg once weekly for 2 weeks followed by high-dose maintenance cidofovir therapy (5 mg/kg)
Study: 9098014
Drug: Noncaloric fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncaloric fruit drink (250 mL)
Study: 7939946
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg polymorph A
Study: 7939946
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg polymorph C
Study: 7939946
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg polymorph C
Study: 7939946
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg polymorph C bid for 3 days (standard dose control)
Study: 23980529
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) or Methotrexate + Cyclosporin A (MTX/CyA) treatment for 1 year
Study: 22537359
Drug: Mecamylamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (0.5 mg/day for 6 weeks, 2.5 mg for 2 weeks, then 5 mg/day for 6 weeks)
Study: 22537359
Drug: Mecamylamine (0.13-0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (0.13-0.15 mg/kg/day)
Study: 22537359
Drug: Mecamylamine (≥0.18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (≥0.18 mg/kg/day)
Study: 20097325
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide implant placement
Study: 20097325
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid therapy (and immunosuppression when indicated)
Study: 18088560
Drug: Dronabinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (10 mg or 20 mg)
Study: 16893381
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tropisetron and dexamethasone
Study: 7513587
Drug: Verbal teaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal teaching and a color‐coded medication schedule
Study: 28993887
Drug: Everolimus 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 4.5 mg/m2/day (target blood trough 5-15 mg/dl)
Study: 27049055
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of emtricitabine (EMT) 200 mg and tenofovir disoproxil fumarate (TNF) 300 mg
Study: 25373630
Drug: Intranasal rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal rapid-acting insulin glulisine
Study: 23287844
Drug: Daily diaries
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily diaries (asthma control days - ACDs)
Study: 17198210
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral dexamethasone (0.6 mg/kg to a maximum of 18 mg)
Study: 17198210
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of twice-daily prednisolone (1 mg/kg per dose to a maximum of 30 mg)
Study: 17198210
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral dexamethasone
Study: 17198210
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of twice-daily prednisolone
Study: 14572560
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (QT)
Study: 14572560
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (DT)
Study: 14572560
Drug: Omeprazole and
Normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole and placebo therapy (OPl)
Study: 8921924
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CsA) at a mean dose of 2.7 +/- 1.1 mg/kg/day (n = 15)
Study: 8921924
Drug: Chloroquine (Chl)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (Chl) at a dose of 100 mg/day (n = 11)
Study: 1633284
Drug: Positron emission
Normalized name: propofol lipid emulsion Injection [Propoven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron emission tomography with H2(15)O injection
Study: 16029791
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with 5-FU (1,000 mg/m2/day for 4 days by continuous infusion Days 2-5 and 28-31) and MMC (10 mg/m2 on Day 2)
Study: 12885977
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 0.6 mg/kg for 14 days
Study: 12885977
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or fluticasone propionate treatment
Study: 10589440
Drug: Balm mint
Normalized name: OCTINOXATE 3.6 g in 1 g / OCTISALATE 2.5 g in 1 g / OXYBENZONE 1.5 g in 1 g TOPICAL LIPSTICK [Lip Balm Mint Flavored]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balm mint cream (1% Lo-701) applied topically four times daily for five days
Study: 10589440
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied topically four times daily for five days
Study: 19204845
Drug: Fluid gel
Normalized name: modified fluid gelatin
DrugBank: Succinylated gelatin (DB16568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid gel
Study: 17043681
Drug: Methenamine Hippurate
Normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine Hippurate (MH) 1 g twice-daily
Study: 17043681
Drug: Cranberry tablets
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry tablets 800 mg twice-daily
Study: 11583639
Drug: Early-switch therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-switch therapy
Study: 11583639
Drug: Parenteral antimicrobials
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antimicrobials
Study: 11583639
Drug: Full course
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full course of parenteral antibiotics
Study: 1319873
Drug: Enoxacin-theophylline administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin-theophylline administration
Study: 30624719
Drug: Edoxaban vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban vs. Warfarin
Study: 18501068
Drug: Capecitabine in
Normalized name: Product containing capecitabine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine in conjunction with radiation therapy
Study: 18501068
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) based chemotherapy
Study: 10492099
Drug: Antenatal TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal TRH 400 microg every eight hours for four doses
Study: 8601364
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ursodeoxycholic acid (UDCA) per day (N = 14)
Study: 8601364
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin per day (N = 14)
Study: 8601364
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control, N = 15)
Study: 30991248
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) at a dosage of 2400 mg/day
Study: 29898192
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 16 sessions
Study: 16135832
Drug: All fluid-treatment
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All fluid-treatment groups
Study: 11806986
Drug: Filgrastim 10
Normalized name: pegfilgrastim 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim 10 microg/kg subcutaneous daily for 5 days
Study: 10430523
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg body weight i.v.)
Study: 7589378
Drug: Short-term inhaled
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term inhaled corticosteroids (200 micrograms b.i.d.) for 4 weeks
Study: 7589378
Drug: Long-term inhaled
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term inhaled corticosteroids (100-1000 micrograms b.i.d.) for less than 6 months
Study: 1981784
Drug: Urine collected
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine collected overnight, expressed as microgram albumin/mg creatinine
Study: 7298846
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDC) 750 mg/d
Study: 7298846
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDC) 375 mg/d
Study: 31625952
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment as usual, n=24)
Study: 26844283
Drug: Stem Cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem Cell Educator (SCE) therapy
Study: 28685960
Drug: SCE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCE therapy
Study: 27097857
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg intranasal midazolam sedation
Study: 27097857
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg sublingual midazolam sedation
Study: 24313543
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal clinical treatment without customised dietary advice)
Study: 22327053
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle intervention with larger monthly weight loss during year 1
Study: 16855765
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tadalafil taken as needed (maximum once daily)
Study: 10805064
Drug: Methoxsalen (CYP2A6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxsalen (CYP2A6 inhibitor)
Study: 10805064
Drug: Troleandomycin (CYP3A4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troleandomycin (CYP3A4 inhibitor)
Study: 10805064
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no inhibitor)
Study: 8877655
Drug: 2% minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% minocycline hydrochloride-gel
Study: 8877655
Drug: Placebo-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-gel
Study: 8877655
Drug: 2% minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% minocycline hydrochloride-gel and Placebo-gel
Study: 1817947
Drug: Preventive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive care program (information on oral hygiene, fluoridation and healthy nutrition, instructions and training) in group 1
Study: 1817947
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of fluoride tablets for babies planned by group 1
Study: 1817947
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of fluoride tablets for babies planned by group 2
Study: 31242936
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (EOF) on post-operative day 1 (POD1)
Study: 31242936
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral feeding (DOF) on post-operative day 4 (POD4)
Study: 19277796
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics for 2 days followed by oral antibiotics for 7 days
Study: 15785008
Drug: Green coffee
Normalized name: Green coffee bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green coffee bean extract (GCE) 140 mg/day for 4 months
Study: 8165852
Drug: DTPw (whole-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw (whole-cell pertussis DTP vaccine)
Study: 26656958
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections with glargine (MDI/G)
Study: 26333503
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration of contrast agent (270 mgI/mL of iodixanol)
Study: 26333503
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration of contrast agent (320 mgI/mL of iodixanol)
Study: 20519679
Drug: Sequential ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ACT (four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel)
Study: 20519679
Drug: Concurrent ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent ACT (four cycles of doxorubicin, cyclophosphamide, and docetaxel)
Study: 20519679
Drug: Sequential ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ACT
Study: 20519679
Drug: Concurrent ACT
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent ACT
Study: 10705222
Drug: Theophylline (200-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200-600 mg/day)
Study: 8465772
Drug: Amiodarone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 600 mg/day for 10 days, followed by 400 mg/day for 10 days, then 200 mg/day for 2 months
Study: 29935528
Drug: Dexmedetomidine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine group (received bupivacaine + 5 mcg dexmedetomidine)
Study: 27924459
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg
Study: 24343824
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of magnesium sulfate and albuterol
Study: 19320802
Drug: Dental and
Normalized name: DENTAL AND ORAL AGENTS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental and periodontal treatments plus oral hygiene education
Study: 19320802
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment approach with only oral hygiene education
Study: 18097211
Drug: Informational program
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informational program regarding influenza vaccine
Study: 15249718
Drug: Irinotecan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 50 mg/m² on days 1, 8, and 15 plus carboplatin (dose escalation starting at AUC 5 mg x min/ml to AUC 6)
Study: 15249718
Drug: Dose level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1 (MTD) of irinotecan and carboplatin
Study: 12733372
Drug: DS 10
Normalized name: amino acids 10 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS 10 mg q.n. for 8 weeks (Group A)
Study: 12733372
Drug: Zocor 10
Normalized name: Zocor 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zocor 10 mg q.n. for 8 weeks (Group B)
Study: 12733372
Drug: DS 10
Normalized name: amino acids 10 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS 10 mg q.n. for 8 weeks (Group C)
Study: 8009591
Drug: BMA 031
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMA 031 (50 mg administered intravenously on the day of, as well as 2 and 4 days after transplantation)
Study: 2623005
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 5.5 mg/kg
Study: 773414
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate 0.1% ointment
Study: 31587084
Drug: G allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: G allele carriers
Study: 31326433
Drug: Glepaglutide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glepaglutide (both doses)
Study: 26822791
Drug: Dronabinol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (5 mg, twice daily)
Study: 24062400
Drug: Minimal Residual
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal Residual Disease (MRD) evaluation in bone marrow samples after consolidation therapy
Study: 22288153
Drug: Ladasten (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ladasten (15 mg)
Study: 19637398
Drug: Buspirone (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (15-30 mg/day)
Study: 22129365
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg once daily; open-label treatment for ≥24 months; dose reduction to 4 mg and re-escalation to 8 mg allowed annually
Study: 22129365
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg once daily; open-label treatment for ≥24 months
Study: 10541949
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid regimen (60 ml/kg on day 1, increasing to 150 ml/kg by day 7)
Study: 30478067
Drug: Ticagrelor therapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor therapy for 28 days
Study: 29064792
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg once a day